+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Next Generation Sequencing (NGS) Markets in Japan

  • ID: 5204241
  • Report
  • November 2020
  • Region: Japan
  • 310 Pages
  • AcuBiz Consulting Sdn Bhd
1 of 4
An In-Depth Look at the NGS Market Growth Trends in the Clinical as well as Non-Clinical Segments in Japan (2019-2024 Period), along with the Impact of COVID-19 in 2020 and its Impact in the Demand Forecast

FEATURED COMPANIES

  • 10x Genomics Inc
  • BGI Group
  • F. Hoffman-La Roche Ltd
  • GeneQuest Co., Ltd
  • Macrogen, Inc
  • Perkin Elmer, Inc
  • MORE

This report analyses the market trends influencing various NGS market segments in Japan. It also analyses the global market trends, which have a significant impact in Japan's NGS market. It covers a detailed analysis of the impact of COVID-19 in each market segment.

This is an updated version of the study conducted in 2019. The estimations and forecasts in the original version have been revisited for accommodating the impact COVID-19, which has affected all the sub-segments across the NGS markets in Japan. The base year of the study is maintained as 2019 since the pandemic situation is still evolving and impact is uncertain to a large extent. The original estimates for each market segment have been revised for 2020 and beyond in this updated version. Response to COVID-19 by each leading market player in Japan has also been evaluated in detail.

This report segments Japan’s NGS market with respect to methods, applications, and product as well as service types. The drivers and restraints of segments are evaluated for estimating market size, forecast and COVID-19 impact. The profiles of leading players in the global, as well as Japanese markets, are studied in detail along with their response to the pandemic and impact on their NGS revenues in 2020. The report also includes a detailed analysis of the regulatory as well as the reimbursement landscapes in Japan that play a major role in shaping the NGS market, particularly related to the clinical diagnostics end-use segments. The report has a total of 310 pages, which includes more than 50 tables.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 10x Genomics Inc
  • BGI Group
  • F. Hoffman-La Roche Ltd
  • GeneQuest Co., Ltd
  • Macrogen, Inc
  • Perkin Elmer, Inc
  • MORE

Executive Summary

  • Summary Table: the NGS Market Size and Forecast in Japan (USD, Million)
  • Impact of COVID-19 Pandemic

Market Overview

  • NGS Workflow
    • Library Preparation and Amplification
    • Sequencing
    • Data Analysis
  • NGS Market Trends
    • Market Drivers
    • Technological Advancements
    • Declining Costs
    • Precision Medicine Initiatives
    • Health Insurance Coverage
    • Increasing Demand from Clinical Applications Segments
    • Growing Investments in Companion Diagnostics (CDx) Development
  • Market Restraints
    • Impact of COVID-19
    • High Costs Compared to Alternative Genomic Platforms
    • Lack of Effective Software Solutions for Data Management and Downstream Analysis
    • NSG Data Management, Interpretation and Sharing: Ethical and Legal Issues
    • Lack of Geneticists
    • Lack of Awareness
    • Market Entry Barriers for New Comers
  • Health Insurance Landscape in Japan
    • Table 1: Government Agencies Responsible for Health Policy in Japan
    • Public Health Insurance in Japan
    • Residence-based National Health Insurance (NHI)
    • Employer-based Health Insurance
    • Health Insurance for the Elderly
    • Private Health Insurance in Japan
    • Reimbursement Fee Decision Process in Japan
    • Health Insurance Coverage for Sequencing Tests
    • Table 2: NGS-based Clinical Diagnostics Tests with Insurance Coverage in Japan
  • Regulatory Landscape Promoting NGS in Japan
    • Regulatory Options for NGS-based Tests
    • Genomic Data Sharing Policies
    • Regulatory Process for Companion Diagnostics
    • Table 3: Regulatory Process for Companion Diagnostics Approval in Japan
  • The NGS Market Landscape in Japan
    • Industry Consolidation Trends
    • Setbacks to Industry Consolidation
    • Partnerships Focusing on NGS Services and Other Segments
  • NGS Market in Japan and Impact of COVID-19 Pandemic
    • Table 4: the NGS Market Size and Forecast in Japan (2019-2024; USD, Million)

NGS Markets in Japan by Methods

  • Targeted Genome Sequencing and Resequencing
    • Table 5: NGS Panels Approved for Clinical Diagnostics Applications in Japan
  • Whole Genome Sequencing (WGS)
    • Large-Scale WGS Studies on Japanese Population
    • Table 6: Selected List of Large-Scale WGS Projects in Japan
    • Table 7: Selected List of Organisations Conducting Large-Scale WGS Projects in Japan
  • Whole Exome Sequencing (WES)
    • Table 8: Selected List of Large Scale WES Projects in Japan
  • RNA-Seq
    • Commercial Platforms, Kits and Data Analysis Products for RNA-seq
    • Table 9: Selected List of Companies Offering RNA-Seq Library Preparation Kits
    • mRNA-Seq
    • Non-Coding RNA-seq
    • Single-cell RNA-seq (scRNA-seq)
    • Table 10: Selected Cell Isolation and Library Preparation Platforms in the Market for scRNA-Seq
    • Table 11: Selected List of scRNA-Seq Data Analysis Products
    • Transcriptomics Moving from Microarrays to RNA-seq
  • Other NGS Methods
    • The Market Size and Growth Trends of the Leading NGS Methods
    • Table 12: the NGS Market Size and Forecast in Japan by Method (2019-2024; USD, Million)

NGS Markets in Japan by Products and Services

  • Instruments
    • Single Cell Sequencing
    • Table 13: Popular NGS Platforms in the Japanese Market
    • NGS Workflow Automation Products
    • Table 14: Selected List of Products Facilitating Automation of NGS and their Suppliers
  • Consumables and Accessories
    • Table 15: Selected List of NGS Library Preparation Products in Japan for Research Use
  • Bioinformatics Tools for NGS
    • Primary Data Analysis
    • Secondary Data Analysis
    • Tertiary Data Analysis
    • Table 16: Commonly Used Bioinformatic Tools for NGS: for Primary, Secondary, and Tertiary Data Analysis
    • Rising Influence of Cloud Computing
    • Key Challenges of NGS Data Analysis Players
    • Role of Reference Laboratories as NGS Moves to Clinical Diagnostics in Japan
    • NGS Data Analysis in Japan: Key Players and Capabilities
    • NGS Service Providers in Japan
    • Table 17: Selected List of Leading NGS service Providers in Japan
  • NGS Market Size and Growth Trends in Japan by Products and Services
    • Table 18: the NGS Market Size and Forecasts in Japan by Products and Services (2019-2024; USD, Million)

NGS Markets in Japan by Application Segments

  • Clinical Diagnostics
    • The Clinical Genetics Medical Care System in Japan
    • Table 19: Selected List of Associations influencing Clinical Genetics in Japan
    • Genetic Counsellor Certification System in Japan
    • Concerns Regarding Genetic Information Abuse Potentials
    • NGS-based Cancer Diagnostics in Japan
    • Regulations Influencing NGS-based Cancer Diagnosis in Japan
    • Table 20: the Basic Plan to Promote Cancer Control Programs in Japan
    • Guidelines for NGS-based Gene Panel Tests for Cancer in Japan
    • Table 21: Evidence Levels as per the Guidance for Gene Panel Testing of Solid Cancers in Japan
    • NGS-based CDx Tests for Cancer in Japan: Regulations and Reimbursement Status
    • Concerns about Accuracy of NGS-based Cancer Diagnostics for Japanese Population
    • Gene Panel Tests Dominate NGS-based Cancer Diagnostics Segment
    • Approved NGS-based Gene Panel Tests for Cancer in Japan
    • Table 22: NGS-based Gene Panel Tests for Cancer Diagnostics in Japan
    • Reimbursement for Gene Panel Tests for Cancer in Japan
    • NGS-based Cancer Diagnostics: Infrastructure and Other Challenges in Japan
    • NGS-based Precision Oncology Initiatives and their Influence in Clinical Diagnostics in Japan
    • Influence of Academia in Driving Gene Panel Tests Demand
    • The Future of NGS-based Cancer Diagnostics in Japan
    • Table 23: Core Hospitals Designated for Cancer Genomic Medicine across Japan
    • NGS-based Reproductive Health Diagnostics in Japan
    • The Rising Global Demand for NIPT
    • Table 24: Diseases and Aneuploidies Commonly Tested by NIPT Assays
    • Table 25: Selected List of NGS-based NIPT Tests in the Global Market
    • NIPT Market – an Assessment of the IP Landscape of NGS Platforms
    • Rising Investments in the New-born and Prenatal Testing Markets
    • Prenatal Testing Insurance Coverage Status: Japan VS Other Regulated Markets
    • Reproductive Health Focus of the Japanese Society and Bioethics Concerns
    • Regulatory Status of Preimplantation Genetic Testing (PGT) in Japan
    • Availability of NGS-based New-born and Prenatal Tests in Japan
    • Table 26: New-born Screening Program in Japan: Incidences of Diseases Targeted
    • The Issue of Unauthorised NIPT Service Providers in Japan
    • NGS Demand in Other Clinical Diagnostics Segments
    • Infectious Diseases
    • Tuberculosis
    • SARS-CoV-2 Testing
    • HLA Typing
  • Direct-to-Consumer (DTC) Genetic Testing
    • The Evolving Regulatory Landscape of DTC Genetic Testing
    • Regulatory Scrutiny Triggering Novel Consumer Genomics Business Models
    • Legal Framework for DTC Genetic Testing in Japan
    • Genomic Software Firms Filling the Gap of Genetic Counsellors
    • Online Availability of DTC Genetic Tests
    • Acceptance of DTC Genetic Tests in Medical Fields
    • Status of DTC Genetic Testing in Japan
    • Emerging Consumer Genomics Applications Attracting New Investments in Japan
  • Research Applications
    • Academic Research
    • Table 27: Selected Institutions in Japan Active in NGS Research/ Research Services
    • Large-Scale Genome-wide Sequencing Projects in Japan
    • Table 28: Selected List of Large Scale Genome-wide Sequencing (GWS) Projects in Japan
    • Influence of Public-Private Partnership
    • Industry R&D
    • Other Emerging NGS Application Segments
    • Table 29: the NGS Market Size and Forecasts in Japan by Application Segments (2019-2024; USD, Million)

Company Profiles

  • 10x Genomics, Inc
    • 10x Genomics Products and Response to COVID-19
    • Table 30: Selected List of NGS Products Offered by 10x Genomics
    • Impact of COVID-19 Pandemic
    • Acquisitions and Partnerships
    • Table 31: Selected List of Partnerships and Acquisitions of 10x Genomics
    • Activities in the Japanese Market
  • Agilent Technologies
    • NGS Products Offered by Agilent
    • Impact of COVID-19 in Agilent’s NGS Business
  • BGI Group
    • BGI Genomics Co Ltd and MGI Tech
    • Table 32: Sequencers Produced and Marketed by the BGI Group
    • Table 33: NGS-based Assays and Services Provided by BGI Group
    • Partnerships and Collaborations
    • Table 34: Selected List of Recent Partnerships of BGI Group*
    • Response to COVID-19
    • BGI in Japan’s NGS Market
  • Eurofins Scientific S.E.
    • Global Expansion through Innovation and Acquisitions
    • Role in the NGS Market
    • Response to COVID-19
    • Presence in Japan’s NGS Market
  • F. Hoffmann-La Roche Ltd
    • Response to COVID-19
    • NGS Products and Services
    • Table 35: Acquisitions and Partnerships Related to Roche’s NGS Business
    • Japan Updates
  • Foundation Medicine, Inc.
    • Products and Services
    • Impact of COVID-19 Pandemic
    • Partnerships
    • Table 36: Selected List of Partnerships and Collaborations of Foundation Medicine
    • Foundation Medicine in Japan
  • Genesis Healthcare Co., Japan
    • Products and Services
    • Table 37: Genetic Testing offered under GeneLife Brand by Genesis Healthcare
  • GeneQuest Co. Ltd.
  • Genewiz (Japan Genewith Co,, Ltd)
    • Role in the NGS Market
    • Activities in Japan
  • Illumina
    • Expanding Consumer Segments
    • NGS Business – Strategies, Products, and Services
    • Table 38: Selected List of Sequencing Systems offered by Illumina
    • Table 39: Selected List of Assays Offered by Illumina
    • Response to COVID-19 Pandemic
    • Focus on Innovation and Related Investments
    • Clinical Diagnostics Strategies
    • Table 40: Selected List of Partnerships Targeting Diagnostics Applications
    • Illumina in Japan’s NGS Market
  • Macrogen Inc
    • NGS Services Offered by Macrogen
    • Table 41: Gene Panel Tests Offered by Macrogen
    • Collaborations and Partnerships
    • Table 42: Selected List of Partnerships and Collaborations of Macrogen*
    • Response to COVID-19
    • Activities in the Japanese Market
  • Oxford Nanopore Technologies
    • Table 43: Sequencers produced by Oxford Nanopore Technologies
    • Response to COVID-19 Pandemic
    • Partnerships and Collaborations
    • Table 44: Selected List of Recent Partnerships of Oxford Nanopore Technologies
    • Activities in the Japanese Market
  • Pacific Biosciences of California, Inc
    • Table 45: Selected List of the Products Offered by PacBio
    • Partnerships and Collaborations
    • Table 46: Selected List of Partnerships of PacBio in the last 5 years
    • Impact of COVID-19 Pandemic
    • Activities in Japan’s NGS Market
  • Perkin Elmer Inc.
    • Response to COVID-19
    • NGS Products and Services
    • Table 47: Selected NGS Products of Perkin Elmer
    • Perkin Elmer in Japan
  • Qiagen N. V.
    • COVID-19 Pandemic Effect on NGS Business
    • NGS business of Qiagen
    • Qiagen in Japan’s NGS Market
  • RIKEN Genesis Co. Ltd.
    • Partnerships
    • Table 48: Selected List of Partnerships of RIKEN Genesis
  • Sysmex Corporation
    • Response to COVID-19
    • Role in Japan’s NGS Market
  • Takara Bio Inc
    • NGS Products and Services
    • Impact of the COVID-19 pandemic
    • Partnerships and Agreements
    • Table 49: Partnerships and Collaborations of Takara Bio in the past 5 years
  • Thermo Fisher Scientific Inc.
    • Response to COVID-19 pandemic
    • Partnerships and Acquisitions
    • Table 50: Selected Partnerships and Acquisitions of Thermo Fisher (2017-2020)
    • NGS Products and Services
    • Table 51: NGS Instruments Offered by Thermo Fisher Scientific
    • Table 52: Selected List of NGS-based Assays and Services of Thermo Fisher Scientific
    • Thermo Fisher Scientific in Japan’s NGS Market

Glossary

List of Tables

  • Summary Table: the NGS Market Size and Forecast in Japan (Usd, Million)
  • Table 1: Government Agencies Responsible for Health Policy in Japan
  • Table 2: NGS-Based Clinical Diagnostics Tests with Insurance Coverage in Japan
  • Table 3: Regulatory Process for Companion Diagnostics Approval in Japan
  • Table 4: The NGS Market Size and Forecast in Japan (2019-2024; USD, Million)
  • Table 5: NGS Panels Approved for Clinical Diagnostics Applications in Japan
  • Table 6: Selected List of Large-Scale Wgs Projects in Japan
  • Table 7: Selected List of Organisations Conducting Large-Scale Wgs Projects in Japan
  • Table 8: Selected List of Large Scale Wes Projects in Japan
  • Table 9: Selected List of Companies Offering Rna-Seq Library Preparation Kits
  • Table 10: Selected Cell Isolation and Library Preparation Platforms in the Market for Scrna-Seq
  • Table 11: Selected List of Scrna-Seq Data Analysis Products
  • Table 12: the NGS Market Size and Forecast in Japan by Method (2019-2024; USD, Million)
  • Table 13: Popular NGS Platforms in the Japanese Market
  • Table 14: Selected List of Products Facilitating Automation of NGS and their Suppliers
  • Table 15: Selected List of NGS Library Preparation Products in Japan for Research Use
  • Table 16: Commonly Used Bioinformatic Tools for NGS: for Primary, Secondary, and Tertiary Data Analysis
  • Table 17: Selected List of Leading NGS Service Providers in Japan
  • Table 18: the NGS Market Size and Forecasts in Japan by Products and Services (2019-2024; USD, Million)
  • Table 19: Selected List of Associations Influencing Clinical Genetics in Japan
  • Table 20: the Basic Plan to Promote Cancer Control Programs in Japan
  • Table 21: Evidence Levels As Per the Guidance for Gene Panel Testing of Solid Cancers in Japan
  • Table 22: NGS-Based Gene Panel Tests for Cancer Diagnostics in Japan
  • Table 23: Core Hospitals Designated for Cancer Genomic Medicine Across Japan
  • Table 24: Diseases and Aneuploidies Commonly Tested by Nipt Assays
  • Table 25: Selected List of NGS-Based Nipt Tests in the Global Market
  • Table 26: New-Born Screening Program in Japan: Incidences of Diseases Targeted
  • Table 27: Selected Institutions in Japan Active in NGS Research/ Research Services
  • Table 28: Selected List of Large Scale Genome-Wide Sequencing (Gws) Projects in Japan
  • Table 30: Selected List of NGS Products Offered by 10X Genomics
  • Table 31: Selected List of Partnerships and Acquisitions of 10X Genomics
  • Table 32: Sequencers Produced and Marketed by the Bgi Group
  • Table 33: NGS-Based Assays and Services Provided by Bgi Group
  • Table 34: Selected List of Recent Partnerships of Bgi Group*
  • Table 35: Acquisitions and Partnerships Related to Roche’S NGS Business
  • Table 36: Selected List of Partnerships and Collaborations of Foundation Medicine
  • Table 37: Genetic Testing Offered Under Genelife Brand by Genesis Healthcare
  • Table 38: Selected List of Sequencing Systems Offered by Illumina
  • Table 39: Selected List of Assays Offered by Illumina
  • Table 40: Selected List of Partnerships Targeting Diagnostics Applications
  • Table 41: Gene Panel Tests Offered by Macrogen
  • Table 42: Selected List of Partnerships and Collaborations of Macrogen*
  • Table 43: Sequencers Produced by Oxford Nanopore Technologies
  • Table 44: Selected List of Recent Partnerships of Oxford Nanopore Technologies
  • Table 45: Selected List of the Products Offered by Pacbio
  • Table 46: Selected List of Partnerships of Pacbio in the Last 5 Years
  • Table 47: Selected NGS Products of Perkin Elmer
  • Table 48: Selected List of Partnerships of Riken Genesis
  • Table 49: Partnerships and Collaborations of Takara Bio in the Past 5 Years
  • Table 50: Selected Partnerships and Acquisitions of Thermo Fisher (2017-2020)
  • Table 51: NGS Instruments Offered by Thermo Fisher Scientific
  • Table 52: Selected List of NGS-Based Assays and Services of Thermo Fisher Scientific
Note: Product cover images may vary from those shown
3 of 4

FEATURED COMPANIES

  • 10x Genomics Inc
  • BGI Group
  • F. Hoffman-La Roche Ltd
  • GeneQuest Co., Ltd
  • Macrogen, Inc
  • Perkin Elmer, Inc
  • MORE

Japan had contributed significantly to the Human Genome Project completed in 2001 and has been able to maintain a critical mass of skilled manpower who could drive genomics research and its applications in the country. They have been receiving considerable support from the government as well, which has enabled the country to make significant progress in many aspects related to genomics.

Globally, the genomics field is witnessing massive changes during the past few decades. Technologies such as PCR and microarrays have fundamentally changed the landscape of several application segments. Currently, NGS is influencing similar changes, but at an accelerated pace. Some of the key factors driving the increased acceptance of NGS by various end-use segments include improvements in affordability, ease of use, and data analysis capabilities. Overall, there has been a significant reduction in the cost of sequencing per base during the past five years.

Automated NGS workflow solutions have played a major role in the adoption of NGS in many targeted markets. Integration of the sequencing process with automated sample preparation, library preparation and data analysis steps has helped laboratories to scale up their NGS services, which assisted in reducing their services fees. The advancement in data analysis solutions is another factor that has enabled the adoption of NGS end-users in various non-clinical application areas such as food testing, and forensics.

Significant challenges still exist for NGS that limit their growth potentials. For instance, the cost is still much higher compared to the other genomic platforms. In addition to the capital costs associated with establishing NGS workflows, the laboratories also need to budget for high recurring costs for expensive consumables as well as reagents. High costs are also involved in hiring and retaining a skilled workforce for NGS operations. The costs for maintaining large data storage and data analysis facilities can also increase the budget significantly.

In terms of application segments, clinical diagnostics applications are expected to drive the demand for in Japan. The advent of simpler benchtop sequencers has played a critical role in improving precision medicine awareness. NGS-based clinical diagnostics are being approved for insurance coverage by the government agencies, which is expected to drive the demand in the clinical diagnostics segments grow at a CAGR of about 24 per cent during the forecast period.

The Japanese government is making significant investments to promote the potential of precision medicine in the country and there are many on-going large scale NGS-based genomics projects that support this goal. This is a key driver of NGS demand from research groups. NGS-based methods are also being used by various industry R&D groups for various applications including clinical research and companion diagnostics development. Another key application area that had indicated significant growth potentials in 2019 was Direct-to-Consumer (DTC) genetic testing. As other application segments, this segment was also affected significantly in 2020 as the demand declined due to the pandemic. Together, non-clinical segments are expected to drive the demand for NGS at a CAGR of about 9 per cent during the forecast period. Overall, Japan has been slow to adopt NGS for clinical applications due to cost concerns and the pressure it can add to the country’s National Health Insurance budget. As a result, non-clinical segments account for over 80 per cent of Japan’s NGS market at present.

In terms of NGS methods, targeted sequencing-based on gene panels accounts for about 46 per cent of Japan’s NGS market. It is also expected to grow at a CAGR of over 13 per cent during the forecast period. Other NGS methods that are expected to grow at a double-digit growth rate during the forecast period include whole genome sequencing and RNA-sequencing. Within the products and services segments, consumables account for over 60 per cent of the NGS market in Japan, while services including bioinformatics solutions is the second largest segment accounting for over 30 per cent of the market.

Overall, the NGS market in Japan is expected to grow at a CAGR of 12.1 per cent between 2019 and 2024. The market segments are already indicating signs of recovery. Though the impact is expected to linger for a while, the NGS market is expected to recover during the forecast period driven by the demand from various application segments as various NGS methods such as WGS and RNA-seq find increasing acceptance end-users in various application segments.

Note: Product cover images may vary from those shown
4 of 4
  • 10x Genomics Inc
  • Agilent Technologies
  • BGI Group
  • Eurofins Scientific
  • F. Hoffman-La Roche Ltd
  • Foundation Medicine, Inc.
  • GeneQuest Co., Ltd
  • Genesis Healthcare Co., Japan
  • Genewiz (Japan Genewith Co., Ltd)
  • Illumina
  • Macrogen, Inc
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Perkin Elmer, Inc
  • Qiagen N. V.
  • Riken Genesis Co., Ltd
  • Sysmex Corporation
  • Takara Bio Inc
  • Thermo Fisher Scientific
Note: Product cover images may vary from those shown
Adroll
adroll